October 8, 2024Open Access

Cost‐effectiveness of finerenone added to standard of care for patients with type 2 diabetes‐related chronic kidney disease in the United States

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

For patients with T2DM-related CKD, adding finerenone to SoC may be a cost-effective option in the United States. Reasonable price reductions for finerenone could potentially benefit more patients.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Zheng et al. (Tue,) studied this question.

synapsesocial.com/papers/69e11cb9af805784e5557781 https://doi.org/https://doi.org/10.1111/dom.15997

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)2022 · 79 citations
2Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design2018 · 7 citations
3Preference-Based EQ-5D Index Scores for Chronic Conditions in the United States2006 · 720 citations
4US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States2019 · 988 citations
5FP374HEALTH STATE UTILITY OF CKD PATIENTS WITH HYPERKALEMIA: ANALYSIS OF EQ-5D IN A REAL WORLD POPULATION ACROSS THE EU-5, CHINA AND USA2019 · 3 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo